The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2024

Filed:

May. 25, 2020
Applicant:

Qingdao Restore Biotechnology Co., Ltd., Qingdao, CN;

Inventors:

Bingqiang Zhang, Shandong, CN;

Mengmeng Chen, Shandong, CN;

Wei Zou, Qingdao, CN;

Xueqi Fu, Qingdao, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/079 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0621 (2013.01); C12N 2500/30 (2013.01); C12N 2501/14 (2013.01); C12N 2501/235 (2013.01); C12N 2501/37 (2013.01); C12N 2506/1346 (2013.01);
Abstract

A serum-free complete medium for inducing differentiation of a mesenchymal stem cell to a corneal epithelial cell in the field of differentiation induction of stem cells, prepared by the following method: uniformly mixing the serum-free complete medium, containing 5-10 μmol of resveratrol, 2-4 μmol of icariin, 1-3 nmol of aspirin, 1-3 nmol of parathyroid hormone, 5-10 nmol of hydrocortisone, 1-3 mg of rapamycin, 2-10 μg of testosterone, 2-10 μg of EPO, 2-10 μg of LIF and the balance of a corneal epithelial cell serum-free medium in per 1 L; and then performing sterilization by filtration. The disclosure uses resveratrol and icariin in combination with aspirin, parathyroid hormone, hydrocortisone, rapamycin, testosterone and growth factors to cooperatively induce directional differentiation, uses nontoxic induction components, is high in induction efficiency and short in induction time, and achieves high induced corneal epithelial cell activity, no cell transplantation rejection, no ethical problem and high safety.


Find Patent Forward Citations

Loading…